Home Healthcare  Summary CYTK has begun its US launch of Myqorzo. So far, its early prescribing demand seems promising, and they’re moving towards its full commercial ramp. Additionally, aficamten recently met both primary endpoints in Phase 3 ACACIA-HCM for non-obstructive HCM. Similarly, CYTK’s MAPLE-HCM sNDA has been accepted, with a November 2026 PDUFA date. CYTK’s balance sheet also appears quite liquid today. After their recent equity offering, I estimate they now have a comfortable cash runway. Unfortunately, I feel CYTK’s valuation is now much more expensive than when I first covered it. So, ideally, I think you should wait for a dip before adding more shares. J Studios/DigitalVision via Getty Images Cytokinetics, Incorporated ( CYTK ) is a specialty biopharma that commercializes Myqorzo (aficamten). Myqorzo is approved in the US, China, and the EU for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with additional applications studied in late-stage trials.…